Ensysce Biosciences, Inc. (ENSC) Q2 2026 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Ensysce Biosciences, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:02.612 Greetings and welcome to the Ensysce Biosciences, Inc. 00:00:02.612 -- 00:00:07.332 Corporate Update Call. At this time, all participants are in a listen-only mode. 00:00:07.332 -- 00:00:11.373 If anyone should require operator assistance, please press star zero on your telephone 00:00:11.373 -- 00:00:14.834 keypad. It is now my pleasure to introduce your host, Dr. 00:00:14.834 -- 00:00:17.274 Lynn Kirkpatrick, Chief Executive Officer. 00:00:17.274 -- 00:00:20.355 Thank you. You may begin. 00:00:20.715 -- 00:00:23.656 Thank you, Operator. And good morning, everyone. 00:00:23.656 -- 00:00:29.451 Thank you for joining us. We recently issued a press release outlining our acquisition 00:00:29.451 -- 00:00:31.032 of SciBioPharma 00:00:31.032 -- 00:00:34.335 and a concurrent private placement financing. 00:00:34.335 -- 00:00:40.540 That release, along with an updated corporate presentation, is available at 00:00:40.540 -- 00:00:42.181 www.Ensysce.com 00:00:42.181 -- 00:00:45.063 under the Investors section. 00:00:45.063 -- 00:00:50.307 Before we begin, I would like to remind everyone that statements made during this 00:00:50.307 -- 00:00:55.715 call that are not historical facts including statements relating to NCIS's 00:00:55.715 -- 00:01:01.077 expected future performance, future business prospects and future events 00:01:01.077 -- 00:01:06.639 or plans and the anticipated benefits of the transaction may be forward-looking 00:01:06.639 -- 00:01:13.621 statements within the meaning of the Private Securities Litigation Reform Act of 1995. 00:01:13.722 -- 00:01:19.064 All such forward-looking statements are intended to be subject of the safe harbor 00:01:19.064 -- 00:01:24.249 protection provided by the Reform Act. These statements are ba...